ArticleDigestive diseases and sciences2026
Kaempferol Ameliorates Functional Constipation in Mice by Regulating Autophagy of Interstitial Cells of Cajal via the p53/AMPK/mTOR Axis.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ferulic Acid Prevents the Hepatotoxicity of AFB1 on Broilers via Regulating Autophagy.Veterinary sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundFunctional constipation (FC) is a prevalent gastrointestinal disorder, and abnormal autophagy in interstitial cells of Cajal (ICCs) has been implicated in its pathogenesis. Kaempferol, a natural flavonoid, shows therapeutic potential for constipation, though its precise mechanism remains unclear.
aimThis study aimed to investigate whether kaempferol alleviates FC by modulating autophagy in ICCs through the p53/AMPK/mTOR signaling pathway.
methodsA mouse model of FC was established using loperamide (10 mg/kg/day) for 14 d. Animals received kaempferol (15, 30, or 60 mg/kg) or mosapride for 7 d. Constipation symptoms were evaluated by measuring fecal water content and intestinal propulsion rate. Colon tissue damage was assessed histologically, and c-Kit expression was analyzed via qRT-PCR and immunohistochemistry. Autophagy activity and pathway protein expression were examined using transmission electron microscopy and Western blot. In vitro experiments utilized L-glutamate-stimulated ICCs with the mTOR agonist MHY1485 for mechanistic validation.
resultsKaempferol significantly improved constipation symptoms, increased c-Kit expression, and alleviated colon tissue damage in FC mice. It effectively suppressed excessive autophagy in ICCs, demonstrated by reduced autophagosome formation, decreased LC3-II/LC3-I ratio and Beclin1, and increased p62. Mechanistically, kaempferol activated the p53/AMPK/mTOR pathway both in vivo and in vitro, elevating p53 and p-mTOR while reducing p-AMPK expression. The anti-autophagic effect was enhanced by MHY1485.
conclusionKaempferol ameliorates functional constipation by inhibiting excessive autophagy in ICCs via activation of the p53/AMPK/mTOR pathway, providing new insights into its mechanism and supporting its potential as a therapeutic agent for FC.
Indexed as
Identifiers
41240265What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.